Inovio Pharmaceuticals CEO J Kim's 2021 pay jumps 32% to $6.2M
Inovio Pharmaceuticals reports 2021 executive compensation
By ExecPay News
Published: March 25, 2022
Inovio Pharmaceuticals reported fiscal year 2021 executive compensation information on March 25, 2022.
In 2021, four executives at Inovio Pharmaceuticals received on average a compensation package of $3.3M, a 18% increase compared to previous year.
Average pay of disclosed executives at Inovio Pharmaceuticals
J. Joseph Kim, Chief Executive Officer, received $6.2M in total, which increased by 32% compared to 2020. 42% of Kim's compensation, or $2.6M, was in option awards. Kim also received $451K in non-equity incentive plan, $844K in salary, $2.3M in stock awards, as well as $13K in other compensation.
For fiscal year 2021, the median employee pay was $180,313 at Inovio Pharmaceuticals. Therefore, the ratio of J. Joseph Kim's pay to the median employee pay was 35 to one.
Jacqueline E. Shea, Chief Operating Officer, received a compensation package of $2.3M, which increased by 8% compared to previous year. 37% of the compensation package, or $861K, was in option awards.
Peter D. Kies, Chief Financial Officer, earned $2.3M in 2021, a 7% increase compared to previous year.
Laurent M. Humeau, Chief Scientific Officer, received $2.3M in 2021, which increases by 7% compared to 2020.
Related executives
You may also like
Source: SEC filing on March 25, 2022.